BACKGROUND & AIMS: Refractory celiac disease (RCD) occurs when both symptoms and intestinal damage persist or recur despite strict adherence to a gluten-free diet. In RCD, the immunophenotype of intraepithelial lymphocytes may be normal and polyclonal (RCD I) or abnormal and monoclonal (RCD II). The aim is to describe the clinical characteristics, treatment, and long-term outcome in a large single-center cohort of patients with RCD. METHODS: We compared the clinical characteristics and outcome in 57 patients with RCD: 42 with RCD I and 15 with RCD II. RESULTS: Fifteen of 57 patients died during follow-up (n=8 with RCD I and n=7 with RCD II), each within the first 2 years after RCD diagnosis. The overall 5-year cumulative survival is 70%, 80%, and 45% for the entire cohort, RCD I, and RCD II, respectively. The refractory state itself and enteropathy-associated T-cell lymphoma (EATL) were the most common causes of death, respectively. A new staging system is proposed based on the cumulative effect of 5 prognostic factors investigated at the time of the refractory state diagnosis: for patients in stages I, II, and III, the 5-year cumulative survival rate was 96%, 71%, and 19%, respectively (P< .0001). CONCLUSIONS: RCD is associated with high mortality with RCD II having an especially poor prognosis because of the development of EATL. A new staging model is proposed that may improve the precision of prognosis in patients with RCD.
BACKGROUND & AIMS: Refractory celiac disease (RCD) occurs when both symptoms and intestinal damage persist or recur despite strict adherence to a gluten-free diet. In RCD, the immunophenotype of intraepithelial lymphocytes may be normal and polyclonal (RCD I) or abnormal and monoclonal (RCD II). The aim is to describe the clinical characteristics, treatment, and long-term outcome in a large single-center cohort of patients with RCD. METHODS: We compared the clinical characteristics and outcome in 57 patients with RCD: 42 with RCD I and 15 with RCD II. RESULTS: Fifteen of 57 patients died during follow-up (n=8 with RCD I and n=7 with RCD II), each within the first 2 years after RCD diagnosis. The overall 5-year cumulative survival is 70%, 80%, and 45% for the entire cohort, RCD I, and RCD II, respectively. The refractory state itself and enteropathy-associated T-cell lymphoma (EATL) were the most common causes of death, respectively. A new staging system is proposed based on the cumulative effect of 5 prognostic factors investigated at the time of the refractory state diagnosis: for patients in stages I, II, and III, the 5-year cumulative survival rate was 96%, 71%, and 19%, respectively (P< .0001). CONCLUSIONS: RCD is associated with high mortality with RCD II having an especially poor prognosis because of the development of EATL. A new staging model is proposed that may improve the precision of prognosis in patients with RCD.
Authors: Daniel A Leffler; Melinda Dennis; Brian Hyett; Eoin Kelly; Detlef Schuppan; Ciaran P Kelly Journal: Clin Gastroenterol Hepatol Date: 2007-03-26 Impact factor: 11.382
Authors: Wieke H M Verbeek; Marije S Goerres; B Mary E von Blomberg; Joost J Oudejans; Petra E T Scholten; Muhammed Hadithi; Abdul Al-Toma; Marco W J Schreurs; Chris J J Mulder Journal: Clin Immunol Date: 2007-11-26 Impact factor: 3.969
Authors: A Al-Toma; W H M Verbeek; O J Visser; K C Kuijpers; J J Oudejans; H C Kluin-Nelemans; C J J Mulder; P C Huijgens Journal: Dig Liver Dis Date: 2007-05-24 Impact factor: 4.088
Authors: Salma Akram; Joseph A Murray; Darrell S Pardi; Glenn L Alexander; John A Schaffner; Pierre A Russo; Susan C Abraham Journal: Clin Gastroenterol Hepatol Date: 2007-08-01 Impact factor: 11.382
Authors: Pardeep Brar; Susie Lee; Suzanne Lewis; Ikenna Egbuna; Govind Bhagat; Peter H R Green Journal: Am J Gastroenterol Date: 2007-06-20 Impact factor: 10.864
Authors: Greetje J Tack; Wieke H M Verbeek; Abdul Al-Toma; Dirk J Kuik; Marco W J Schreurs; Otto Visser; Chris J J Mulder Journal: World J Gastroenterol Date: 2011-01-28 Impact factor: 5.742
Authors: David S Atlas; Alberto Rubio-Tapia; Carol T Van Dyke; Brian D Lahr; Joseph A Murray Journal: Gastrointest Endosc Date: 2011-08-11 Impact factor: 9.427
Authors: R L J van Wanrooij; D M J Müller; E A Neefjes-Borst; J Meijer; L G Koudstaal; D A M Heideman; H J Bontkes; B M E von Blomberg; G Bouma; C J J Mulder Journal: J Clin Immunol Date: 2014-07-27 Impact factor: 8.317
Authors: Hugh James Freeman; Angeli Chopra; Michael Tom Clandinin; Alan Br Thomson Journal: World J Gastroenterol Date: 2011-05-14 Impact factor: 5.742
Authors: P Nijeboer; Rlj van Wanrooij; T van Gils; N J Wierdsma; G J Tack; B I Witte; H J Bontkes; O Visser; Cjj Mulder; G Bouma Journal: United European Gastroenterol J Date: 2016-06-23 Impact factor: 4.623